These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34808661)

  • 1. A size and space structured model of tumor growth describes a key role for protumor immune cells in breaking equilibrium states in tumorigenesis.
    Atsou K; Anjuère F; Braud VM; Goudon T
    PLoS One; 2021; 16(11):e0259291. PubMed ID: 34808661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mixture-like model for tumor-immune system interactions.
    Fotso CT; Girel S; Anjuère F; Braud VM; Hubert F; Goudon T
    J Theor Biol; 2024 Mar; 581():111738. PubMed ID: 38278343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A size and space structured model describing interactions of tumor cells with immune cells reveals cancer persistent equilibrium states in tumorigenesis.
    Atsou K; Anjuère F; Braud VM; Goudon T
    J Theor Biol; 2020 Apr; 490():110163. PubMed ID: 31981572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the Equilibrium Phase in Immune-Controlled Tumors Provides Hints for Designing Better Strategies for Cancer Treatment.
    Atsou K; Khou S; Anjuère F; Braud VM; Goudon T
    Front Oncol; 2022; 12():878827. PubMed ID: 35832538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical modeling of hypoxia and adenosine to explore tumor escape mechanisms in DC-based immunotherapy.
    Ghiyabi E; Arabameri A; Charmi M
    Sci Rep; 2024 May; 14(1):11387. PubMed ID: 38762567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD147‑mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment (Review).
    Li X; Xu W
    Oncol Rep; 2019 May; 41(5):2945-2956. PubMed ID: 30864716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma-delta (γδ) T cells: friend or foe in cancer development?
    Zhao Y; Niu C; Cui J
    J Transl Med; 2018 Jan; 16(1):3. PubMed ID: 29316940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual role of complement in cancers, from destroying tumors to promoting tumor development.
    Lu P; Ma Y; Wei S; Liang X
    Cytokine; 2021 Jul; 143():155522. PubMed ID: 33849765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy.
    Conciatori F; Bazzichetto C; Falcone I; Ciuffreda L; Ferretti G; Vari S; Ferraresi V; Cognetti F; Milella M
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32727102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innate lymphoid cells and cancer: Role in tumor progression and inhibition.
    Yuan X; Rasul F; Nashan B; Sun C
    Eur J Immunol; 2021 Sep; 51(9):2188-2205. PubMed ID: 34189723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?
    Tolle F; Umansky V; Utikal J; Kreis S; Bréchard S
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
    Cui Y; Guo G
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major fundamental factors hindering immune system in defense against tumor cells: The link between insufficiency of innate immune responses, metabolism, and neurotransmitters with effector immune cells disability.
    Bahrambeigi S; Sanajou D; Shafiei-Irannejad V
    Immunol Lett; 2019 Aug; 212():81-87. PubMed ID: 31260743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune microenvironments in solid tumors: new targets for therapy.
    Shiao SL; Ganesan AP; Rugo HS; Coussens LM
    Genes Dev; 2011 Dec; 25(24):2559-72. PubMed ID: 22190457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil Heterogeneity in Cancer: From Biology to Therapies.
    Lecot P; Sarabi M; Pereira Abrantes M; Mussard J; Koenderman L; Caux C; Bendriss-Vermare N; Michallet MC
    Front Immunol; 2019; 10():2155. PubMed ID: 31616408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of CXC Chemokine Receptors 1-4 on Immune Cells in the Tumor Microenvironment.
    Susek KH; Karvouni M; Alici E; Lundqvist A
    Front Immunol; 2018; 9():2159. PubMed ID: 30319622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer.
    Anari F; Ramamurthy C; Zibelman M
    Future Oncol; 2018 Jun; 14(14):1409-1421. PubMed ID: 29848096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy.
    Tuccitto A; Shahaj E; Vergani E; Ferro S; Huber V; Rodolfo M; Castelli C; Rivoltini L; Vallacchi V
    Virchows Arch; 2019 Apr; 474(4):407-420. PubMed ID: 30374798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape.
    Wenbo L; Wang J
    J R Soc Interface; 2017 Jun; 14(131):. PubMed ID: 28659412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.